ARS Pharmaceuticals Inc expected to post a loss of 12 cents a share - Earnings Preview

ARS Pharmaceuticals

06/08/2024 12:06

* ARS Pharmaceuticals Inc  SPRY.OQ   SPRY.O  is expected
to show a
rise in quarterly revenue when it reports  results on August 8
(estimated) for the period ending June 30 2024
    * The San Diego California-based  company is expected to
report a
9,900.0% increase in revenue to $1 million from $10 thousand a
year ago, according to the mean estimate from 2 analysts, based
on LSEG data.
    * ​LSEG's mean analyst estimate for ARS Pharmaceuticals Inc
is for
a loss of 12 cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 3 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for ARS
Pharmaceuticals Inc is $18.50​, above​ its last closing price
of $9.32. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Mar. 31 2024  -0.12       -0.11      -0.11     Met     0
 Dec. 31 2024  -0.11       -0.14      -0.07     Beat    50
 Sep. 30 2023  -0.19       -0.18      -0.16     Beat    12.4​
 Jun. 30 2023  -0.19       -0.17      -0.18     Missed  -3.6
 ​​Mar.        -0.17       -0.17      -0.16     Beat    4.6
 31 2023                                                
 Dec. 31 2022  -0.13       -0.13      0.77      Beat    692.3​
 Jan. 1 0001   -0.35       -0.35      -0.50     Missed  -40.8
 Jun. 30 2022  -0.50       -0.48      -0.55     Missed  -13.8
 This summary was machine generated August 6 at 11:06 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)